Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

er cancer patients has been initiated that will test immediate post operative (IPOP) intravesical administration of Chemophase, the combination of rHuPH20 with mitomycin C immediately following transurethral resection of bladder tumor (TURBT). Results of this small safety study will be used to support the inclusion of the IPOP dosing regimen as part of the protocol in future Chemophase studies. Halozyme is making preparations to meet with regulatory authorities during the first half of 2009 to discuss the trial design for potential registration studies.

-- Halozyme hosted its first Research Day for financial analysts and the investment community on October 6, 2008 in New York. The well attended event provided a forum for an in depth presentation and discussion by the Halozyme management team of its proprietary product development pipeline, its plans for future clinical trials, and its business strategy. A replay of the meeting can be found on the Halozyme website. (http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-calendar)

-- The company has recently strengthened its senior management team with the addition of Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development, Patrick O'Connor, Ph.D., Vice President, Research, Michael J. LaBarre, Ph.D., Vice President, Product Development, and James E. Cartoni, Vice President, Legal. Successfully recruiting, developing, and retaining high caliber, experienced executives exemplifies Halozyme's commitment to exceptional talent.

-- Positive pre-clinical animal efficacy data (http://www.halozyme.com/2008AACRTCsk-4%20-%20large.pdf)were presented for PEGPH20 at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, Calif. on July 21, 2008. The study demonstrat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... has commenced a public offering of shares of ... its common stock and overallotment purchase rights to ... of common stock, warrants and overallotment purchase rights ...
(Date:5/27/2015)... The Academy of Model Aeronautics Foundation would ... Model Aviation Day. The third annual celebration will be August ... the model aviation hobby nation-wide and to introduce model flying ... 2,350 chartered clubs to celebrate the hobby and share it ... There will also be a local event at the AMA ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... May 27, 2015  CytomX, a biotechnology company ... today announced the appointments of Bob Goeltz ... Ladd as senior vice president and general ... financial officer of Onyx Pharmaceuticals, an Amgen subsidiary. ... and legal counsel to several leading biotech companies, ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3
... Jointly Offer "Always on," Secure Solution For Mobile ... (Nasdaq:ADCT; www.adc.com ) and Network365 announced today a ... solution that helps generate additional revenue for mobile ... and trusted m-commerce transactions between operators, banks and ...
... a year in which Wisconsins real-time economy gained time ... news stories suggests the state is becoming a place where ... the champagne corks just yet: Wisconsin still has a long ... high-wage jobs as the state lost in the three-year manufacturing ...
... began requiring applicants to pay significant user fees when ... biologics. Such user fees have long been required for ... related to devices and biologics. In theory, user fees ... at what cost? User fees impose a significant financial ...
Cached Biology Technology:ADC and Network365 Team to Offer New End-to-End Mobile Payment System 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 2The (Tech) Economic Year in Review: Signs of Progress Amid Continuing Challenges 3Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden? 2
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... research shows some bees brace themselves against wind and turbulence ... approach comes at a steep cost, increasing aerodynamic drag and ... cutting into the bees, flight performance. The findings ... of Sciences . "Wind is a universal part of ...
... Calif. June 2 , 2009 SRI International, an ... results are now available from the Advanced Modular Incoherent ... by the National Science Foundation (NSF) that has recently ... Scientists are using the novel system to investigate ...
... "You are what you eat." Can these pithy words explain the ... Harvard University, who argues in a new book that the invention ... or the advent of tools -- is what led to the ... Us Human," is published today (June 1) by Basic Books. In ...
Cached Biology News:Trading energy for safety, bees extend legs to stay stable in wind 2SRI International announces findings from new upper atmospheric radar system for scientific research 2SRI International announces findings from new upper atmospheric radar system for scientific research 3SRI International announces findings from new upper atmospheric radar system for scientific research 4Harvard scientist says we are what we eat -- and what we cook 2
LEAF™ Purified anti-human/mouse/rat ICOS...
Purified anti-human CD182 (CXCR2)...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Request Info...
Biology Products: